SUPN — Supernus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.80bn
- $1.34bn
- $661.82m
- 100
- 62
- 90
- 98
Annual cashflow statement for Supernus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 127 | 53.4 | 60.7 | 1.32 | 73.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 29.3 | 42.5 | 19 | 59.8 | 39.9 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -36.5 | 3.57 | -22.1 | -9.14 | -2.05 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 138 | 127 | 117 | 111 | 172 |
| Capital Expenditures | -3.45 | -2.04 | -0.412 | -0.551 | -0.725 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -31.3 | -79.9 | -216 | 269 | -189 |
| Acquisition of Business | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -34.7 | -81.9 | -217 | 269 | -190 |
| Financing Cash Flow Items | 0 | — | -22.9 | -1.99 | -2.71 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.56 | -130 | -10.5 | -398 | 12.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 107 | -85.2 | -110 | -18.1 | -5.72 |